Sutro Bio - רווח נקי למניה בארבעת הרבעונים האחרונים STRO

The price history of Sutro Biopharma, Inc. (STRO) reflects an EPS TTM of 51.30. Sutro Biopharma, Inc. (STRO) attracts leading oncobiologists by offering them cutting-edge laboratories and stock options. The business is currently focused on developing less toxic targeted therapies and is in the clinical trial stage. However, geopolitical instability and the severance of scientific ties create risks for the timely completion of trials for new treatment methods.

This metric measures the annual change in net profit per share over the last twelve months, reflecting the efficiency of profit generation relative to inflationary pressure and rising costs. By analyzing the current EPS YoY TTM trend, an investor assesses the margin stability of Sutro Biopharma, Inc. (STRO), considering the risks of dependence on external contract manufacturers when scaling drug production.